Clinical Trial Results for Daroxonasib
In a Phase 3 clinical trial, the experimental drug daroxonasib significantly improved survival rates for patients with pancreatic cancer. Patients receiving the new treatment had a median survival of 13.2 months, a marked improvement over the 6.7 months seen with standard second-line chemotherapy. The drug also reduced the risk of death by 60% and doubled the time before disease progression, from 3.6 months to 7.2 months.
Study Details
The Phase 3 trial enrolled 500 participants from North America, Europe, and Asia. The overall objective response rate for the new drug was 31.6%, compared to just 11.2% for chemotherapy. Notably, over 90% of pancreatic tumors carry KRAS oncogene mutations, and daroxonasib works by blocking these specific mutations.
Findings from the trial were published in The New England Journal of Medicine. Common side effects associated with daroxonasib included:
- rash
- mouth inflammation
- nausea
- diarrhea
The U.S. Food and Drug Administration (FDA) has already granted an expanded access program for this drug.
“This is the first RAS inhibitor evaluated in a large randomized study for pancreatic cancer patients, and it demonstrates the significant impact these novel drugs are likely to have on disease treatment,” said Brian Wolpin.
Legal disclaimer. This article provides general informational content and should not be considered a substitute for professional medical advice. NV is not responsible for any diagnosis made by readers based on site materials. NV also assumes no liability for the content of external websites linked in this article. If you have health concerns, please consult a physician.
The daroxonasib clinical trial results open new avenues for treating one of the most aggressive cancers, potentially reshaping therapeutic approaches. The survival gains achieved with this drug offer hope to patients and their families while underscoring the need for further research in this area. Given the high prevalence of KRAS oncogene mutations in pancreatic tumors, daroxonasib could become a critical tool in fighting this disease.
As advancements in cancer treatment continue, it's worth noting that another recent study has shown promising results with a new medication, achieving a 40% success rate in patients battling head and neck cancer. This highlights the ongoing progress in the fight against various cancer types, including the encouraging findings from the daroxonasib trial. For more details on this innovative treatment, you can read about it here.